The Epigenetics of Triple-Negative and Basal-Like Breast Cancer: Current Knowledge

Breast cancer has the highest incidence among all malignancies diagnosed in women. Therapies have significantly improved over the years due to extensive molecular and clinical research; in a large number of cases, targeted therapies have provided better prognosis. However, one specific subtype remai...

Full description

Saved in:
Bibliographic Details
Published inJournal of breast cancer Vol. 21; no. 3; pp. 233 - 243
Main Authors Temian, Daiana Cosmina, Pop, Laura Ancuta, Irimie, Alexandra Iulia, Berindan-Neagoe, Ioana
Format Journal Article
LanguageEnglish
Published Korea (South) Korean Breast Cancer Society 01.09.2018
Subjects
Review
DNA methylation
Triple negative breast neoplasms
Breast neoplasms
Untranslated RNA
Histone code
Online AccessGet full text
ISSN1738-6756
2092-9900
DOI10.4048/jbc.2018.21.e41

Cover

More Information
Summary:Breast cancer has the highest incidence among all malignancies diagnosed in women. Therapies have significantly improved over the years due to extensive molecular and clinical research; in a large number of cases, targeted therapies have provided better prognosis. However, one specific subtype remains elusive to targeted therapies-the triple-negative breast cancer. This immunohistochemically defined subtype is resistant to both endocrine and targeted therapies, leading to its poor prognosis. A field that is of great promise in current cancer research is epigenetics. By studying the epigenetic mechanisms underlying tumorigenesis-DNA methylation, histone modifications, and noncoding RNAs-advances in cancer treatment, diagnosis, and prevention are possible. This review aims to synthesize the epigenetic discoveries that have been made related to the triple-negative breast cancer.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
ObjectType-Review-3
content type line 23
ISSN:1738-6756
2092-9900
DOI:10.4048/jbc.2018.21.e41